Clinical trial · Observational
Application of Megavoltage Imaging to Reduce Artifact After Seed Implants
Application of Megavoltage Imaging to Reduce Artifact Following Interstitial Seed Implants for Prostate Adenocarcinoma
NCT01810627CI-TRIAL-00029659completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a non-randomized study to evaluate the utility of MVCT as a quality assurance measure in patients treated with interstitial permanent seed implants for low and intermediate risk prostate cancer. All patients will received the same standard of care treatment but will receive an additinoal CT image of the prostate.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MVCT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- MVCT
- description
- Patients will receive an additional MVCT scan at their one month follow up visit.
- interventionNames
- Radiation: MVCT
Primary outcomes (1)
- measure
- Change in prostate volume measured in cm^3
- timeFrame
- One month post implant
- description
- Change in prostate volume measured with trans-rectal ultrasound at baseline versus prostate volume measured with KVCT and MVCT.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: Male 50-80 years of age Eligible for interstitial brachytherapy implants Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.